QL47

QL47 is a small molecule that functions as a **potent, covalent, and selective inhibitor of Bruton’s tyrosine kinase (BTK)**, acting by covalently modifying the Cys481 residue and thereby inhibiting BTK kinase activity. QL47 inhibits BTK with an IC50 of approximately 7 nM, and induces G1 cell cycle arrest with pronounced degradation of BTK protein in B-cell lymphoma cell lines, exhibiting antiproliferative effects at submicromolar concentrations. In addition, **QL47 acts as a broad-spectrum antiviral agent** by selectively inhibiting eukaryotic translation, thus blocking viral and host protein synthesis at a translation step specific to eukaryotic cells. Evidence indicates that QL47 targets both BTK and BMX and potentially other unknown cellular factors important for viral RNA translation, making it an agent with dual action in oncology and antiviral research. Mechanistic studies suggest its antiviral effect is primarily associated with inhibition of translation of viral genomes and reduction in steady-state abundance of viral proteins. QL47 is not recommended for in vivo studies due to poor microsomal stability but is widely used in research settings[1][3][4][5][7][8].

Other names

BMX/BTK Inhibitor IIBTK Inhibitor VBMX Inhibitor IITEC Inhibitor IIPI 3-K Inhibitor XXIPI3-K Inhibitor XXIPI-3-K Inhibitor XXIBLK Inhibitor II